Ondine Biomedical Inc.
OBI.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £2 | £1 | £1 | £3 |
| % Growth | 70.3% | 88.6% | -75.2% | – |
| Cost of Goods Sold | £1 | £1 | £0 | £1 |
| Gross Profit | £1 | £1 | £0 | £1 |
| % Margin | 64.5% | 58.4% | 45% | 48.8% |
| R&D Expenses | £9 | £5 | £6 | £5 |
| G&A Expenses | £10 | £8 | £11 | £13 |
| SG&A Expenses | £11 | £10 | £12 | £13 |
| Sales & Mktg Exp. | £1 | £2 | £1 | £0 |
| Other Operating Expenses | £1 | £1 | £0 | £0 |
| Operating Expenses | £21 | £16 | £19 | £19 |
| Operating Income | -£19 | -£15 | -£19 | -£18 |
| % Margin | -949% | -1,230.7% | -2,940.9% | -682% |
| Other Income/Exp. Net | £0 | £0 | -£1 | -£33 |
| Pre-Tax Income | -£19 | -£14 | -£19 | -£50 |
| Tax Expense | £0 | £0 | £0 | £0 |
| Net Income | -£19 | -£14 | -£19 | -£50 |
| % Margin | -932.1% | -1,198% | -3,036.4% | -1,949.6% |
| EPS | -0.07 | -0.073 | -0.1 | -0.26 |
| % Growth | 4.2% | 26.9% | 61.5% | – |
| EPS Diluted | -0.07 | -0.073 | -0.1 | -0.26 |
| Weighted Avg Shares Out | 275 | 197 | 195 | 195 |
| Weighted Avg Shares Out Dil | 275 | 197 | 195 | 195 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £1 |
| Depreciation & Amortization | £1 | £1 | £0 | £1 |
| EBITDA | -£18 | -£14 | -£19 | -£48 |
| % Margin | -902.2% | -1,146.1% | -2,954.4% | -1,882.4% |